As December 2025 unfolds, global markets are closely watching the Federal Reserve's final meeting of the year, with hopes for an interest rate cut buoying investor sentiment. Amidst these macroeconomic developments, penny stocks in Asia continue to draw attention for their potential to deliver value and growth opportunities that larger firms might miss. While the term "penny stocks" may seem outdated, it remains relevant as these smaller or newer companies can offer compelling investment opportunities with robust financials and a clear growth trajectory.
Top 10 Penny Stocks In Asia
| Name |
Share Price |
Market Cap |
Financial Health Rating |
| JBM (Healthcare) (SEHK:2161) |
HK$2.68 |
HK$2.19B |
★★★★★★ |
| Lever Style (SEHK:1346) |
HK$1.46 |
HK$903.04M |
★★★★★★ |
| TK Group (Holdings) (SEHK:2283) |
HK$2.56 |
HK$2.12B |
★★★★★★ |
| CNMC Goldmine Holdings (Catalist:5TP) |
SGD0.975 |
SGD395.16M |
★★★★★☆ |
| T.A.C. Consumer (SET:TACC) |
THB4.94 |
THB2.96B |
★★★★★★ |
| Atlantic Navigation Holdings (Singapore) (Catalist:5UL) |
SGD0.103 |
SGD53.92M |
★★★★★★ |
| Yangzijiang Shipbuilding (Holdings) (SGX:BS6) |
SGD3.48 |
SGD13.7B |
★★★★★☆ |
| F & J Prince Holdings (PSE:FJP) |
₱2.21 |
₱843.44M |
★★★★★★ |
| Livestock Improvement (NZSE:LIC) |
NZ$1.00 |
NZ$142.34M |
★★★★★★ |
| Scott Technology (NZSE:SCT) |
NZ$3.02 |
NZ$252.29M |
★★★★★☆ |
Click here to see the full list of 970 stocks from our Asian Penny Stocks screener.
Let's explore several standout options from the results in the screener.
Beijing Biostar Pharmaceuticals
Simply Wall St Financial Health Rating:★★★★★★
Overview:Beijing Biostar Pharmaceuticals Co., Ltd. is a synthetic biology-driven biopharmaceutical company focused on the research, development, manufacture, and commercialization of oncology products in China with a market cap of HK$717.35 million.
Operations:The company's revenue segment is derived entirely from pharmaceuticals, totaling CN¥53.53 million.
Market Cap:HK$717.35M
Beijing Biostar Pharmaceuticals, with a market cap of HK$717.35 million, focuses on oncology products in China and has generated CN¥53.53 million in revenue. The company is debt-free and boasts a strong cash runway exceeding three years, supported by its substantial short-term assets of CN¥644.0 million surpassing both short- and long-term liabilities. Despite being unprofitable with negative return on equity (-17.05%), it has managed to reduce losses over the past five years by 1.9% annually. However, its share price remains highly volatile, reflecting broader challenges within the biotech sector's earnings landscape.
Viva Goods
Simply Wall St Financial Health Rating:★★★★★☆
Overview:Viva Goods Company Limited is an investment holding company that supplies apparel and footwear across various regions including the United Kingdom, the Republic of Ireland, the United States, China, Asia, Europe, the Middle East, and Africa with a market cap of HK$6.37 billion.
Operations:The company's revenue is primarily derived from its Multi-Brand Apparel and Footwear segment, generating HK$9.58 billion, followed by the Sports Experience segment with HK$558.53 million.
Market Cap:HK$6.37B
Viva Goods Company Limited, with a market cap of HK$6.37 billion, primarily generates revenue from its Multi-Brand Apparel and Footwear segment (HK$9.58 billion). Despite being unprofitable with a negative return on equity (-2%), the company has reduced its debt to equity ratio significantly over five years, now at 13.2%, and maintains a satisfactory net debt to equity ratio (0.3%). Short-term assets of HK$5.7 billion comfortably cover both short- and long-term liabilities, while the management team is experienced with an average tenure of 6.1 years, contributing to operational stability amidst earnings challenges.
-
Jump into the full analysis health report here for a deeper understanding of Viva Goods.
-
Assess Viva Goods' previous results with our detailed historical performance reports.
Xiamen Hexing Packaging Printing
Simply Wall St Financial Health Rating:★★★★★★
Overview:Xiamen Hexing Packaging Printing Co., Ltd. operates in the packaging and printing industry, with a market cap of CN¥5.61 billion.
Operations:The company generates CN¥10.63 billion in revenue from its packaging manufacturing industry segment.
Market Cap:CN¥5.61B
Xiamen Hexing Packaging Printing Co., Ltd. operates with a market cap of CN¥5.61 billion and reported revenues of CN¥7.74 billion for the first nine months of 2025, down from CN¥8.59 billion the previous year, yet net income increased to CN¥159.61 million from CN¥144.42 million, indicating improved profitability despite revenue challenges. The company's seasoned management and board contribute to its operational stability, with debt levels well-managed as evidenced by a satisfactory net debt to equity ratio of 17.8% and strong interest coverage at 4.9x EBIT, though earnings growth remains negative over recent years amidst high share price volatility.
Where To Now?
-
Unlock our comprehensive list of 970 Asian Penny Stocks by clicking here.
-
Ready For A Different Approach? AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SEHK:2563 SEHK:933 and SZSE:002228.
This article was originally published by Simply Wall St .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
